Melissa Palmer

Melissa Palmer
Palmer in November 2009
Born (1958-08-29) August 29, 1958 (age 66)
New York City, U.S.
NationalityAmerican
EducationMedical Degree, Mount Sinai School of Medicine, 1985; Residency in Internal Medicine, Mount Sinai Beth Israel, 1985-88; Fellowship in Hepatology, Mount Sinai School of Medicine, 1988-89; Fellowship in Gastroenterology, Stony Brook University Hospital, 1989-91
OccupationChief Medical Officer
SpouseAlan Pressman (m. 1987)

Melissa Palmer (born August 29, 1958) is an American hepatologist. She is recognized for her research and treatment of hepatitis and liver disease. Palmer is the Chief Medical Officer of Gannex Pharma, a wholly owned company of Ascletis Pharma.[1][2]

Early life and education

[edit]

Palmer was born in New York City. She grew up in Forest Hills, Queens and attended Forest Hills High School. She attended Columbia University,[3] where she obtained a Bachelor of Science. She attended medical school at the Mount Sinai School of Medicine, where she received a Doctor of Medicine degree in 1985.[4]

Career

[edit]

Palmer completed her internship and residency at Mount Sinai Beth Israel in Manhattan, New York, from 1985 to 1988, and completed a fellowship in Hepatology at Mount Sinai. Palmer also completed a Gastroenterology fellowship at Stony Brook University Hospital.[5]

It was during her fellowship at Mount Sinai that Palmer became the first to publish research demonstrating that if an overweight person who has liver-related abnormalities (such a person is considered to have NAFLD) loses 10% of their body weight, it corrects these findings. Non-alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease worldwide, occurring in 30-40 percent of adults in the United States.[6] This research study,[7] published in the medical journal Gastroenterology in 1990, has been cited in almost 500 medical research articles. In addition, Palmer, either as primary author or co-author, published several guidelines with colleagues from the Food and Drug Administration (FDA) concerning how to detect, assess and manage suspected drug induced liver injury (hepatotoxicity) among patients participating in clinical trials evaluating potential drugs to treat liver diseases such as NASH, PBC, PSC, Viral Hepatitis B and C, and cirrhosis.[8][9][10]

Palmer is the author of the book "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease" which is notable for being a comprehensive book on liver disease written for the general public as well as health care practitioners. Published in 2000, the book provides information on all facets of liver disease, including the function of the liver, liver blood tests, the symptoms and treatment of various liver diseases, cirrhosis, liver cancer, and the influence of lifestyle on liver disease. The book has been translated into several languages, including Spanish and Chinese. Palmer also co-authored and co-edited a medical textbook, The Gastrointestinal and Liver Disease Nutrition Desk Reference, with colleagues from Johns Hopkins Hospital in Baltimore.

Palmer became the Chief Medical Officer of Gannex Pharma as of Dec. 2020. Prior to joining Gannex, she was Head of Liver Disease Clinical Development at Takeda Pharmaceutical Company. She has also held leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of Non-alcoholic steatohepatitis (NASH) and other liver disease programs. Prior to joining the pharmaceutical industry, she was clinical professor at NYU Langone Medical Center. From 1991 to 2011, Palmer operated a solo medical practice focused on liver disease.[11]

Selected publications

[edit]

Books

[edit]
  • "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease"—New Revised Edition May 2004. (PenguinRandomHouse—Avery Division) ISBN 9781583331880 ; Chinese version July 2008. (Jilin Press, Jilin China)
  • "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease"—Original Edition January 1, 2000. (PenguinRandomHouse—Avery Division) ISBN 9781422350898 ; Taiwanese version 2001
  • "The Gastrointestinal and Liver Disease Nutrition Desk Reference", edited by Gerard Mullin,Laura Matarese and Melissa Palmer. Sept. 2011. (CRC Press) ISBN 9781439812648

Chapters

[edit]
  • "Integrative Weight Management: A Guide for Clinicians (Nutrition and Health)"—Chapter on Non-Alcoholic Fatty Liver Disease. Gerald E. Mullin (Editor). May 2014. (Humana Press) ISBN 9781493905478
  • "Textbook of Natural Medicine" 4th Edition—Chapter 173, on Hepatitis. Sept. 2012. (Elsevier) ISBN 9781437723335
  • "Encyclopedia of Plagues, Pestilence and Pandemics"—Chapter on Hepatitis. Oct. 2008 (Greenwood Press) ISBN 9780313341014
  • "Encyclopedia of Science and Technology"—Chapter on Cirrhosis. Feb. 2007. (McGraw-Hill) ISBN 9780071441438
  • "The Autoimmune Connection"—Chapter on AutoImmune Hepatitis/PBC. April 2016. (McGraw-Hill) ISBN 9780071841221

Awards and distinctions

[edit]
  • Fellow of AASLD. 2014–present [12]
  • Medical Advisory Board, Greater New York Chapter of the American Liver Foundation.[13] 1991–present
  • Editorial Board, Practical Gastroenterology.[14] 2009–present

References

[edit]
  1. ^ "Ascletis Pharma".
  2. ^ "Ascletis Pharma Inc. (01672-HK)". biotickr. Retrieved 2022-09-18.
  3. ^ "Columbia University Alumni 1980-1984".
  4. ^ "New York State Department of Health Physician Profile".
  5. ^ "New York State Department of Health Physician Profile".
  6. ^ "NIH--Definition & Facts of NAFLD & NASH".
  7. ^ Palmer, M.; Schaffner, F. (1990). "Effect of weight reduction on hepatic abnormalities in overweight patients". Gastroenterology. 99 (5): 1408–1413. doi:10.1016/0016-5085(90)91169-7. PMID 2210247.
  8. ^ Treem, W. R.; Palmer, M.; Lonjon-Domanec, I.; Seekins, D.; Dimick-Santos, L.; Avigan, M. I.; Marcinak, J. F.; Dash, A.; Regev, A.; Maller, E.; Patwardhan, M.; Lewis, J. H.; Rockey, D. C.; Di Bisceglie, A. M.; Freston, J. W.; Andrade, R. J.; Chalasani, N. (2021). "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis". Drug Safety. 44 (2): 133–165. doi:10.1007/s40264-020-01014-2. PMC 7847464. PMID 33141341.
  9. ^ Palmer, M.; Regev, A.; Lindor, K.; Avigan, M. I.; Dimick-Santos, L.; Treem, W.; Marcinak, J. F.; Lewis, J. H.; Anania, F. A.; Seekins, D.; Shneider, B. L.; Chalasani, N. (2020). "Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease". Alimentary Pharmacology & Therapeutics. 51 (1): 90–109. doi:10.1111/apt.15579. PMC 6972572. PMID 31762074.
  10. ^ Regev, A.; Palmer, M.; Avigan, M. I.; Dimick-Santos, L.; Treem, W. R.; Marcinak, J. F.; Seekins, D.; Krishna, G.; Anania, F. A.; Freston, J. W.; Lewis, J. H.; Sanyal, A. J.; Chalasani, N. (2019). "Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis". Alimentary Pharmacology & Therapeutics. 49 (6): 702–713. doi:10.1111/apt.15153. PMC 6593464. PMID 30761572.
  11. ^ "WebmedCentral".
  12. ^ "AASLD Member Profile".
  13. ^ "American Liver Foundation, New York State Medical Advisory Council".
  14. ^ "Practical Gastroenterology Editorial Board".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Melissa_Palmer&oldid=1248495578"